- Home
- MBRX vs CLDI Comparison
MBRX vs CLDI Comparison
Compare MBRX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | CLDI |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBRX | CLDI |
|---|---|---|
| Price | $2.01 | $0.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $105.50 | N/A |
| AVG Volume (30 Days) | 239.2K | ★ 247.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.22 |
| 52 Week High | $7.98 | $7.32 |
Technical Indicators
Market Signals| Indicator | MBRX | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 19.88 |
| Support Level | $0.37 | $0.22 |
| Resistance Level | $5.22 | $0.51 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 24.83 | 1.39 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.